Spots Global Cancer Trial Database for myeloproliferative neoplasm
Every month we try and update this database with for myeloproliferative neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Prospective Patient Reported Outcomes and Wearables Study in Myeloproliferative Neoplasms | NCT06334913 | Myeloproliferat... | 18 Years - | Guy's and St Thomas' NHS Foundation Trust | ||
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | NCT00723099 | Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg... | Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ... | - 69 Years | Fred Hutchinson Cancer Center | |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | NCT02639559 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Non-Hodgkin's L... Non-Hodgkin Lym... Hodgkin Disease Hodgkins Diseas... Hodgkin's Disea... Multiple Myelom... Myelodysplastic... Myeloproliferat... | BL-8040 Leukapheresis Hematopoietic c... | 18 Years - 75 Years | Washington University School of Medicine | |
| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | NCT04156256 | Hematologic Mal... Acute Myeloid L... Myelodysplastic... Myeloproliferat... Chronic Myeloid... | CD123-CD33 cCAR... | - | iCell Gene Therapeutics | |
| CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | NCT06059391 | Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Myeloid... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Allogeneic Hema... Biospecimen Col... Granulocyte Col... Hematopoietic C... Multi-peptide C... Pheresis Placebo Adminis... Stem Cell Mobil... | 18 Years - | City of Hope Medical Center | |
| The Feasibility of Delivering Consumer-based Meditation Applications to Myeloproliferative Neoplasm Patients | NCT03726944 | Myeloproliferat... | Calm App Medita... Unnamed Consume... Educational Con... | 18 Years - | Arizona State University | |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) | NCT04942080 | Myeloproliferat... Essential Throm... Primary Myelofi... Primary Myelofi... | CALR allele bur... | 18 Years - | University Hospital, Angers | |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | NCT04493138 | Chronic Myelomo... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Myelo... Recurrent Myelo... | Azacitidine Quizartinib | 18 Years - | M.D. Anderson Cancer Center | |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia | NCT02055781 | Primary Myelofi... Post-polycythem... Post-essential ... | Pacritinib Best Available ... | 18 Years - | CTI BioPharma | |
| A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN | NCT05612633 | Accelerated Pha... Blast Phase MPN | zelavespib | 1 Year - 18 Years | Samus Therapeutics, Inc. | |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation | NCT03602898 | Acute Lymphobla... Acute Myeloid L... Chronic Myelomo... Chronic Phase C... Hematopoietic a... Myelodysplastic... Myelofibrosis Myeloproliferat... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Refractory Acut... Therapy-Related... | Anti-Thymocyte ... Busulfan Cyclophosphamid... Cyclosporine Fludarabine Pho... Methotrexate Peripheral Bloo... Quality-of-Life... Questionnaire A... Tacrolimus Total-Body Irra... | - 65 Years | Fred Hutchinson Cancer Center | |
| Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | NCT04146038 | Acute Myeloid L... Chronic Myelomo... Myeloblasts 10 ... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... Secondary Acute... | Azacitidine Decitabine Salsalate Venetoclax | 18 Years - | Rutgers, The State University of New Jersey | |
| Anagrelide Retard in Essential Thrombocythemia | NCT02076815 | Essential Throm... | Anagrelide reta... Thromboreductin | 18 Years - | AOP Orphan Pharmaceuticals AG | |
| 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II | NCT03941769 | Acute Myeloid L... Chronic Myeloge... Cord Blood Tran... Myelodysplastic... Myeloproliferat... | Recombinant Int... | 18 Years - | M.D. Anderson Cancer Center | |
| SARS-CoV-2 Donor-Recipient Immunity Transfer | NCT04666025 | Accelerated Pha... Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Phase C... COVID-19 Infect... Hematopoietic a... Hodgkin Lymphom... Lymphoblastic L... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Biospecimen Col... Diagnostic Labo... Electronic Heal... Questionnaire A... | 18 Years - | City of Hope Medical Center | |
| Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | NCT06013423 | Acute Leukemia ... Acute Lymphobla... Acute Myeloid L... Blastic Plasmac... Hematopoietic a... Mixed Phenotype... Myelodysplastic... Myeloproliferat... Non-Hodgkin Lym... Chronic Myeloid... | Biospecimen Col... Bone Marrow Asp... Cyclophosphamid... Cyclosporine Diagnostic Imag... Echocardiograph... Fludarabine Pho... Multigated Acqu... Mycophenolate M... Survey Administ... Thiotepa Total-Body Irra... Umbilical Cord ... | 6 Months - 65 Years | Fred Hutchinson Cancer Center | |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | NCT02877082 | Acute Leukemia Chronic Lymphoc... Chronic Myeloge... Diffuse Large B... Follicular Lymp... Graft Versus Ho... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... Myelofibrosis Myeloproliferat... Small Lymphocyt... | Thymoglobulin Bortezomib Tacrolimus | 18 Years - 75 Years | Emory University | |
| Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | NCT01822509 | Allogeneic Hema... Myeloproliferat... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Chron... Recurrent Hemat... Recurrent Hodgk... Recurrent Myelo... Recurrent Non-H... Recurrent Plasm... | Ipilimumab Laboratory Biom... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Project: Every Child for Younger Patients With Cancer | NCT02402244 | Carcinoma In Si... Central Nervous... Childhood Immat... Childhood Lange... Childhood Matur... Congenital Meso... Desmoid Fibroma... Ganglioneuroma Lymphoprolifera... Malignant Solid... Melanocytic Neo... Myeloproliferat... Neuroendocrine ... Stromal Neoplas... | Cytology Specim... Medical Chart R... | - 25 Years | Children's Oncology Group | |
| Myeloproliferative Neoplasms (MPN) and COVID-19 | NCT04385160 | Myeloproliferat... COVID | 18 Years - | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | ||
| Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis | NCT01731951 | Primary Myelofi... Secondary Myelo... Myeloid Maligna... | Imetelstat | 18 Years - | Geron Corporation | |
| Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | NCT06218628 | Primary Myelofi... Post-polycythem... Post-essential ... Chronic Myelomo... Polycythemia Ve... Essential Throm... | Talazoparib pacritinib | 18 Years - | Fox Chase Cancer Center | |
| Evaluation of New Biomarkers of Thrombosis in Myeloproliferative Neoplasms | NCT04177576 | Myeloproliferat... | 2 additional tu... | 18 Years - | University Hospital, Bordeaux | |
| Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr) | NCT05419648 | Myeloproliferat... | 1 additional tu... | 18 Years - | University Hospital, Bordeaux | |
| Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | NCT02566304 | Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto... | Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom... | 18 Years - | Thomas Jefferson University | |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04493164 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... | Ivosidenib Liposome-encaps... | 18 Years - | M.D. Anderson Cancer Center | |
| PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation | NCT05120570 | Acute Leukemia Myelodysplastic... Myeloproliferat... Lymphoma | VIC- 1911 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy | NCT04014764 | Acute Myelogeno... Multiple Myelom... Myelodysplastic... Lymphoma Acute Lymphobla... Chronic Myeloge... Myeloproliferat... | This is a non-i... | 18 Years - | Notable Labs | |
| Project: Every Child for Younger Patients With Cancer | NCT02402244 | Carcinoma In Si... Central Nervous... Childhood Immat... Childhood Lange... Childhood Matur... Congenital Meso... Desmoid Fibroma... Ganglioneuroma Lymphoprolifera... Malignant Solid... Melanocytic Neo... Myeloproliferat... Neuroendocrine ... Stromal Neoplas... | Cytology Specim... Medical Chart R... | - 25 Years | Children's Oncology Group | |
| MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis | NCT04994158 | Myeloproliferat... Splanchnic Vein... JAK2 V617 | Drugs, procedur... | 18 Years - | Royal Free Hospital NHS Foundation Trust | |
| Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | NCT02311569 | Myeloproliferat... Primary Myelofi... Essential Throm... Polycythemia Ve... | Mirabegron | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | NCT05972577 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myeloge... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... Plasma Cell Mye... | Health Promotio... Medical Device ... Quality-of-Life... Questionnaire A... | 60 Years - | Ohio State University Comprehensive Cancer Center | |
| Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome | NCT02521493 | Acute Myeloid L... Down Syndrome Myelodysplastic... Myeloid Leukemi... Myeloproliferat... | Asparaginase Asparaginase Er... Cytarabine Daunorubicin Hy... Etoposide Laboratory Biom... Mitoxantrone Hy... Thioguanine | 91 Days - 3 Years | Children's Oncology Group | |
| The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase | NCT03907436 | Myeloproliferat... Myeloproliferat... Myelofibrosis Polycythemia Ve... Essential Throm... | USDA Diet Mediterranean D... | 18 Years - | University of California, Irvine | |
| Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results | NCT04060485 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Aplastic Anemia | 18 Years - 120 Years | National Taiwan University Hospital | ||
| Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study | NCT05053100 | Acute Leukemia Deep Vein Throm... Hematopoietic a... Hodgkin Lymphom... Myeloproliferat... Non-Hodgkin Lym... Plasma Cell Mye... Thrombocytopeni... | Biospecimen Col... Electronic Heal... | 18 Years - | Mayo Clinic | |
| 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II | NCT03941769 | Acute Myeloid L... Chronic Myeloge... Cord Blood Tran... Myelodysplastic... Myeloproliferat... | Recombinant Int... | 18 Years - | M.D. Anderson Cancer Center | |
| Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes | NCT06361641 | Myeloproliferat... Polycythemia Ve... Essential Throm... Primary Myelofi... | Monocytes signa... | 18 Years - | University Hospital, Angers | |
| Determination of the Clonality Profile in Myeloproliferative Neoplasms and Association With the Thrombotic Complications (CLOJAK) | NCT05839717 | Myeloproliferat... | Blood sampling | 18 Years - | University Hospital, Bordeaux | |
| Asciminib Roll-over Study | NCT04877522 | Chronic Myeloge... Leukemia, Myelo... | Asciminib singl... Asciminib Imatinib Nilotinib Bosutinib Dasatinib | 18 Years - | Novartis | |
| Carotid Plaque Burden in Patients With Philadelphia Negative Myeloproliferative Neoplasms | NCT05993052 | Myeloproliferat... | 18 Years - | Sohag University | ||
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | NCT06001385 | Acute Lymphobla... Acute Myeloid L... Acute Leukemia Myelodysplastic... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Lymphoma Chronic Myelomo... Pro-Lymphocytic... Myelofibrosis | Busulfan Fludarabine PBSC Hematopoie... Post-Transplant... Mesna Tacrolimus Mycophenolate M... Patient Reporte... Melphalan Total-body irra... Cyclophosphamid... | 18 Years - | Center for International Blood and Marrow Transplant Research | |
| Study of DISC-0974 in Participants With Myelofibrosis and Anemia | NCT05320198 | Myelofibrosis; ... Anemia Myelofibrosis Myelofibrosis D... Primary Myelofi... Post-essential ... | DISC-0974 | 18 Years - | Disc Medicine, Inc | |
| A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors | NCT04605211 | Myeloproliferat... Chronic Phase C... Chronic Myeloid... | Online Mindfuln... Internet-Based ... | 18 Years - | University of California, San Francisco | |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | NCT03589729 | Acute Myeloid L... Blast Phase Chr... Blasts 10 Perce... High Risk Myelo... Myeloid Sarcoma Myeloproliferat... Philadelphia Ch... | Cladribine Cytarabine Dexrazoxane Hyd... Gemtuzumab Ozog... Idarubicin | 12 Years - | M.D. Anderson Cancer Center | |
| Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms | NCT05850273 | Myeloproliferat... | 18 Years - | Institut National de la Santé Et de la Recherche Médicale, France | ||
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | NCT01231412 | Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Lymphoc... Diffuse Large B... Hematopoietic a... Indolent Non-Ho... Mantle Cell Lym... Myelodysplastic... Myeloproliferat... Prolymphocytic ... Recurrent Chron... Recurrent Plasm... Refractory Chro... Refractory Chro... Refractory Hodg... Small Lymphocyt... T-Cell Chronic ... Waldenstrom Mac... | Allogeneic Hema... Cyclosporine Fludarabine Pho... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra... | - | Fred Hutchinson Cancer Center | |
| Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) | NCT05177211 | Myeloproliferat... Chronic Neutrop... MDS | Fedratinib Pill | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders | NCT00397813 | Atypical Chroni... Chronic Myelomo... de Novo Myelody... Essential Throm... Myeloproliferat... Paroxysmal Noct... Polycythemia Ve... Polycythemia Ve... Primary Myelofi... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto... | Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Total-Body Irra... | 50 Years - 75 Years | Fred Hutchinson Cancer Center | |
| Olverembatinib for FGFR1-rearranged Neoplasms | NCT05521204 | Myeloproliferat... Acute Leukemia | Olverembatinib | - | The First Affiliated Hospital of Soochow University | |
| CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | NCT03795779 | Hematologic Mal... Acute Myeloid L... Myelodysplastic... Myeloproliferat... Chronic Myeloid... | CLL1-CD33 cCAR ... | - | iCell Gene Therapeutics | |
| MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis | NCT04994158 | Myeloproliferat... Splanchnic Vein... JAK2 V617 | Drugs, procedur... | 18 Years - | Royal Free Hospital NHS Foundation Trust | |
| Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm | NCT04312607 | Myeloproliferat... | BCR-ABL gene PC... | 18 Years - | Assiut University | |
| A New Blood Score for Myelofibrosis Staging | NCT06177366 | Myeloproliferat... | Blood sampling | 18 Years - 100 Years | Assistance Publique - Hôpitaux de Paris | |
| A Study of Zelavespib (PU-H71) in Subjects With AP-MPN or BP-MPN | NCT05612633 | Accelerated Pha... Blast Phase MPN | zelavespib | 1 Year - 18 Years | Samus Therapeutics, Inc. | |
| Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | NCT04146038 | Acute Myeloid L... Chronic Myelomo... Myeloblasts 10 ... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... Secondary Acute... | Azacitidine Decitabine Salsalate Venetoclax | 18 Years - | Rutgers, The State University of New Jersey | |
| Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms | NCT05127174 | Myeloproliferat... | Fedratinib Pill | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms | NCT06284460 | Pathway Mutant ... Myelodysplastic... Myeloproliferat... | ASTX029 ASTX727 | 18 Years - | M.D. Anderson Cancer Center | |
| Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | NCT05745285 | Leukemia Lymphoma Myeloma Myelodysplastic... Myeloproliferat... | LLS Program | 18 Years - | University of Miami | |
| Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant | NCT02506933 | Accelerated Pha... Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Phase C... Cytomegaloviral... Hodgkin Lymphom... Lymphadenopathy Lymphoblastic L... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Laboratory Biom... Multi-peptide C... Placebo | 18 Years - 75 Years | City of Hope Medical Center | |
| Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | NCT04509700 | B-Cell Malignan... | Parsaclisib parsaclisib + i... parsaclisib + r... parsaclisib + i... | 18 Years - | Incyte Corporation | |
| Myeloproliferative Neoplasms (MPNs) Patient Registry | NCT02760238 | Primary Myelofi... Polycythemia Ve... Essential Throm... Mastocytosis Leukemia, Myelo... Leukemia, Myelo... Chronic Eosinop... Myelodysplastic... Neoplasms Leukemia, Myelo... | Observational | - | University Health Network, Toronto | |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT02728050 | Acute Biphenoty... Acute Myeloid L... de Novo Myelody... Myelodysplastic... Myeloproliferat... | Cladribine Cytarabine Filgrastim Laboratory Biom... Quality-of-Life... Mitoxantrone Sorafenib | 18 Years - 60 Years | University of Washington | |
| Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning | NCT04451200 | Acute Leukemia Mielodysplasic ... Myeloproliferat... | Busulfan Inject... | 18 Years - 65 Years | Institut Paoli-Calmettes | |
| Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine | NCT03588078 | Myelodysplastic... Acute Myeloid L... Myeloproliferat... Chronic Myelomo... | APR-246 Azacitidine | 18 Years - | Groupe Francophone des Myelodysplasies | |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | NCT03878199 | Essential Throm... Myelofibrosis Myeloproliferat... Polycythemia Ve... Secondary Acute... | Allogeneic Hema... Liposome-encaps... Ruxolitinib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| SYTHROM Cohort, Myeloproliferative Neoplasia With Normal CBC and Thrombotic Complications | NCT04539678 | Thrombotic Pati... Diagnosis of My... Impact of Treat... | 18 Years - | Nantes University Hospital | ||
| A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | NCT04041050 | Myeloproliferat... | Navitoclax Ruxolitinib Celecoxib | 18 Years - | AbbVie | |
| Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant | NCT04898790 | Leukemia Lymphoma Multiple Myelom... MDS Myeloproliferat... | CHAMPS-II adapt... | 60 Years - | University of Nebraska | |
| Cardiac Changes in Myeloproliferative Neoplasms | NCT03177928 | Myeloproliferat... | Transthorathic ... | - | Assiut University | |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis. | NCT05440838 | Myeloproliferat... | Next-generation... | 18 Years - | University Hospital, Angers | |
| Myeloproliferative Neoplasms (MPNs) Patient Registry | NCT02760238 | Primary Myelofi... Polycythemia Ve... Essential Throm... Mastocytosis Leukemia, Myelo... Leukemia, Myelo... Chronic Eosinop... Myelodysplastic... Neoplasms Leukemia, Myelo... | Observational | - | University Health Network, Toronto | |
| Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | NCT02566304 | Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto... | Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom... | 18 Years - | Thomas Jefferson University | |
| Olverembatinib for FGFR1-rearranged Neoplasms | NCT05521204 | Myeloproliferat... Acute Leukemia | Olverembatinib | - | The First Affiliated Hospital of Soochow University | |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT04493164 | Acute Myeloid L... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... | Ivosidenib Liposome-encaps... | 18 Years - | M.D. Anderson Cancer Center | |
| Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | NCT02564536 | Chronic Myelomo... Juvenile Myelom... Atypical Chroni... Myeloproliferat... Myelodysplastic... Myelofibrosis | Pacritinib Decitabine | 18 Years - | Washington University School of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
